Cancer Acquired Resistance: A New Lesson from Chronic Myelogenous Leukemia
نویسندگان
چکیده
منابع مشابه
Chronic Myelogenous Leukemia: Approaches to Pharmacological Resistance
From 2000 some data relative to IM resistance were available. There are many mechanisms responsible of IM resistance, more often point mutations that cause the progression to blast crisis and death in few months. To circumvent them, more potent TKIs have been subsequently approved [3]. However, another problem arise: these compounds don’t work on all patients because of the different IMresistan...
متن کاملitor Drug Resistance in Chronic Myelogenous Leukemia
ownload pite the initial effectiveness of oncogene-directed cancer therapeutics, acquired drug resistance rethe ultimate “Achilles' heel” for long-term durable remission in cancer patients. Acquisition of drug nce is not more evident elsewhere than in the use of tyrosine kinase inhibitors, imatinib and da, for patients with chronic myelogenous leukemia. Hence, even though imatinib initially pro...
متن کاملOvercoming resistance in chronic myelogenous leukemia.
Chronic myeloid leukemia is defined by the acquired genetic mutation, t(9;22), which leads to the fusion-protein BCR-ABL. Prior to the development of imatinib mesylate (Gleevec), treatment was limited and provided only limited survival benefit. Imatinib has dramatically changed the course of the disease and has led to the significantly prolonged survival in the majority of patients. However, th...
متن کاملCancer Stem Cells in Chronic Myelogenous Leukemia
Chronic Myeloid Leukaemia (CML) is a haematological malignancy that is identified by the presence of a fusion oncogene, BCR-ABL, which is a constitutive tyrosine kinase. The discovery of Tyrosine Kinase Inhibitors (TKIs) over that past decade has resulted in significantly improved survival rates and disease management in CML patients. However, a subpopulation of BCR-ABL1+ cells in the niche are...
متن کاملOverexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells
Imatinib, a breakpoint cluster region (BCR)-Abelson murine leukemia(ABL) tyrosine kinase inhibitor (TKI), has revolutionized the treatment of chronic myelogenous leukemia (CML). However, development of multidrug resistance(MDR) limits the use of imatinib. In the present study, we aimed to investigate the mechanisms of cellular resistance to imatinib in CML. Therefore, we established an imatinib...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Bone Marrow Research
سال: 2013
ISSN: 2329-8820
DOI: 10.4172/2329-8820.1000e101